The content on this site is intended for healthcare professionals only
Dr Velez speaks with ecancertv at the ecancer Colombian Cancer Congress about immunotherapy and CDK4/6 inhibition in the treatment of breast cancer.
Considering preliminary results from immunotherapy trials, he considers how immune modulation might become part of a larger arsenal, in combination or adjuvant settings.
CDK inhibition for breast cancer therapy was discussed further in an expert round-table session at SABCS 2016, and in a special ecancer symposium session at ESMO 2016.
ASCO GU 2026: Updates in bladder cancer
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Choosing Wisely in radiology Tanzania
Overview of the management of HER2-low breast cancer patients
Molecular profiling in prostate cancer: key challenges for clinical implementation
